公开(公告)号：US20160168161A1

公开(公告)日：2016-06-16

申请号：US14907798

申请日：2014-07-22

Applicant: NISSAN CHEMICAL INDUSTRIES, LTD.

Inventor： Akihiro NAGAYA ,  Madoka YOSHINO ,  Hironobu YOSHINO

IPC: C07D491/052 ,  C07C57/145 ,  C07D311/42 ,  C07D311/70

CPC classification number: C07D491/052 ,  C07C57/145 ,  C07D311/42 ,  C07D311/70

Abstract: There is provided a method for producing with a high efficiency a heterocyclic compound that is useful as a raw material for pharamaceuticals. A novel production method for producing 2,2,7,9-tetramethyl-2H-pyrano[2,3-g]quinoline (compound (6)) that has a quinoline ring and a chromene ring using N-(3-acetyl-4-hydroxyphenyl)butylamide (compound (1′)) that is commercially available as a raw material for pharamaceuticals or the like as a starting raw material; and a method for purifying compound (6), characterized by purifying by subjecting it to conversion into a salt form.

Abstract translation: 提供了可用作药物原料的杂环化合物的高效生产方法。 一种具有喹啉环和色烯环的2,2,7,9-四甲基-2H-吡喃并[2,3-g]喹啉（化合物（6））的制备方法，使用N-（3-乙酰基 - 4-羟基苯基）丁酰胺（化合物（1'）），作为起始原料的药物等的原料可商购获得; 和化合物（6）的纯化方法，其特征在于，使其转化成盐形式进行纯化。

公开(公告)号：US09023837B2

公开(公告)日：2015-05-05

申请号：US13641662

申请日：2011-04-15

Applicant: Hirak S. Basu ,  David A. Zarling ,  George Wilding ,  Farideh Mehraein-Ghomi ,  Dawn R. Church

Inventor： Hirak S. Basu ,  David A. Zarling ,  George Wilding ,  Farideh Mehraein-Ghomi ,  Dawn R. Church

IPC: C07D311/42 ,  C07D405/12 ,  C07D311/56 ,  C07D487/04

CPC classification number: C07D311/42 ,  C07D311/56 ,  C07D405/12 ,  C07D487/04

Abstract: Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of cancer.

Abstract translation: 本文描述的是药物组合物和药物，以及在治疗癌症中使用这种药物组合物和药物的方法。

公开(公告)号：US20110045397A1

公开(公告)日：2011-02-24

申请号：US12877345

申请日：2010-09-08

Applicant: Kazuyoshi KURODA ,  Masashi Yasumatsu

Inventor： Kazuyoshi KURODA ,  Masashi Yasumatsu

IPC: G03G9/097

CPC classification number: G03G9/09733 ,  C07D213/68 ,  C07D213/79 ,  C07D213/81 ,  C07D213/82 ,  C07D215/06 ,  C07D215/233 ,  C07D309/38 ,  C07D311/10 ,  C07D311/22 ,  C07D311/42 ,  G03G9/09758

Abstract: A charge control agent having a compound represented by the formula shown below as the active ingredient, as well as a method of controlling the charge of resin powder using the charge control agent, and a toner. X: an oxygen atom or N—H; Each of R1 to R4: a hydrogen atom, a carboxyl group, an aminocarbonyl group having or not having a substituent, an aminocarbonylmethyl group having or not having a substituent, an alkoxycarbonyl group, an alkyl group, a phenyl group having a substituent or not having a substituent, or a group that forms a saturated or unsaturated ring having or not having a substituent in cooperation with any other group selected from among R1 to R4.

Abstract translation: 具有由下述式表示的化合物作为有效成分的电荷控制剂以及使用电荷控制剂控制树脂粉末的电荷的方法和调色剂。 X：氧原子或N-H; R1〜R4各自为氢原子，羧基，具有或不具有取代基的氨基羰基，具有或不具有取代基的氨基羰基甲基，烷氧基羰基，烷基，具有取代基的苯基 或者与选自R 1〜R 4中的任何其它基团配合形成具有或不具有取代基的饱和或不饱和环的基团。

公开(公告)号：US2601204A

公开(公告)日：1952-06-17

申请号：US78631647

申请日：1947-11-15

Applicant: WISCONSIN ALUMNI RES FOUND

Inventor： CAMPBELL HAROLD A ,  STAHMANN MARK A ,  HUEBNER CHARLES F ,  PAUL LINK KARL

IPC: A61K31/37 ,  C07D311/42

CPC classification number: C07D311/42 ,  A61K31/37

公开(公告)号：US20170144965A1

公开(公告)日：2017-05-25

申请号：US15315521

申请日：2015-06-05

Applicant: The University of Kansas

Inventor： Shrikant Anant ,  Dharmalingam Subramaniam ,  Subhash Padhye

IPC: C07C243/38 ,  C07D311/22 ,  C07C49/245 ,  C07C243/18 ,  C07D213/82 ,  C07D307/68 ,  C07D209/18 ,  C07D311/12 ,  C07D213/81

CPC classification number: C07C243/38 ,  A61K47/6951 ,  C07C49/245 ,  C07C243/18 ,  C07D209/18 ,  C07D213/81 ,  C07D213/82 ,  C07D215/12 ,  C07D307/68 ,  C07D311/06 ,  C07D311/12 ,  C07D311/22 ,  C07D311/42

Abstract: A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colorectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds.

公开(公告)号：US20160145247A1

公开(公告)日：2016-05-26

申请号：US14904693

申请日：2014-07-17

Applicant: David B. BELANGER ,  Stefanie FLOHR ,  Christine Fang GELIN ,  Keith JENDZA ,  Nan JI ,  Donglei LIU ,  Edwige Lilliane Jeanne LORTHIOIS ,  Rakeshri Ganesh KARKI ,  Nello MAINOLFI ,  James J. POWERS ,  Stefan Andreas RANDL ,  Olivier ROGEL ,  Anna VULPETTI ,  Taeyoung YOON

Inventor： David Belanger ,  Stefanie Flohr ,  Christine Fang Gelin ,  Keith Jendza ,  Nan Ji ,  Rajeshri Ganesh Karki ,  Donglei Liu ,  Edwoge Liliane Jeanne LORTHIOIS ,  Nello Mainolfi ,  James J. Powers ,  Stefan Andreas Randi ,  Oliver Rogel ,  Anna Vulpetti ,  Taeyoung YOON

IPC: C07D417/12 ,  C07C237/42 ,  C07D263/32 ,  C07D213/56 ,  C07D231/12 ,  C07D307/16 ,  C07D213/81 ,  C07D277/56 ,  C07D213/82 ,  C07D233/90 ,  C07D405/12 ,  C07C311/37 ,  C07D239/26 ,  C07D309/14 ,  C07D309/06 ,  C07C229/34 ,  C07D311/42 ,  C07D317/60 ,  C07D231/56 ,  C07D257/04 ,  C07D265/30 ,  C07D267/10 ,  C07D215/12 ,  C07D205/04 ,  C07D305/06 ,  C07C237/40

CPC classification number: C07D417/12 ,  C07C217/48 ,  C07C217/58 ,  C07C217/64 ,  C07C217/74 ,  C07C217/76 ,  C07C229/34 ,  C07C229/36 ,  C07C229/42 ,  C07C233/43 ,  C07C233/47 ,  C07C233/63 ,  C07C235/34 ,  C07C235/46 ,  C07C237/20 ,  C07C237/38 ,  C07C237/40 ,  C07C237/42 ,  C07C255/16 ,  C07C255/43 ,  C07C255/57 ,  C07C255/59 ,  C07C257/18 ,  C07C311/37 ,  C07C317/32 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D205/04 ,  C07D213/56 ,  C07D213/81 ,  C07D213/82 ,  C07D215/12 ,  C07D231/12 ,  C07D231/56 ,  C07D233/90 ,  C07D239/26 ,  C07D257/04 ,  C07D263/32 ,  C07D265/30 ,  C07D267/10 ,  C07D277/56 ,  C07D305/06 ,  C07D307/16 ,  C07D309/06 ,  C07D309/14 ,  C07D311/42 ,  C07D317/60 ,  C07D405/12

Abstract: The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract translation: 本发明提供了式（I）化合物，本发明化合物的制备方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。

公开(公告)号：US20160066603A1

公开(公告)日：2016-03-10

申请号：US14785566

申请日：2013-04-18

Applicant: EMPIRE TECHNOLOGY DEVELOPMENT LLC

Inventor： Georgius Abidal ADAM ,  Scott Andrew NEEDHAM

IPC: A23L1/03 ,  A23L1/304 ,  C07D311/42 ,  C07C65/11 ,  C07C323/62 ,  C07C62/32

CPC classification number: C07C62/32 ,  A23L29/035 ,  A23L33/16 ,  A23L33/165 ,  C07C65/05 ,  C07C65/11 ,  C07C323/62 ,  C07C2601/16 ,  C07C2602/10 ,  C07D311/42

Abstract: Disclosed are antioxidative, natural compounds, their salts, chelates and cleavage derivatives that exhibit a superior combination of properties. The compounds can be used for a variety of purposes, including stabilizing foods, cosmetics, beverages and nutritional supplements. The compounds can be prepared by hydrolyzing a fulvic acid of formula I or VIII to provide at least one antioxidant compounds of formula II, formula III, formula IV, formula V, formula VI, formula VII, salts, or chelates thereof.

Abstract translation: 公开了表现出优异的性能组合的抗氧化天然化合物，其盐，螯合物和裂解衍生物。 该化合物可用于多种用途，包括稳定食品，化妆品，饮料和营养补充剂。 该化合物可以通过水解式I或VIII的富里酸来制备，以提供至少一种式II，式III，式IV，式V，式VI，式Ⅶ的抗氧化剂化合物，其盐或螯合物。

公开(公告)号：US20150299156A1

公开(公告)日：2015-10-22

申请号：US14437859

申请日：2013-11-27

Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED

Inventor： Yosuke NAKASHIMA ,  Yoshinobu Jin

IPC: C07D311/42 ,  C07D405/12 ,  A01N43/40 ,  A01N43/78 ,  A01N43/60 ,  A01N43/58 ,  C07D409/12 ,  C07D417/12 ,  A01N43/16 ,  A01N43/54

CPC classification number: C07D311/42 ,  A01N43/16 ,  A01N43/40 ,  A01N43/54 ,  A01N43/58 ,  A01N43/60 ,  A01N43/78 ,  C07D309/32 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention provides a compound having an excellent efficacy for controlling weeds. A dihydropyrone compound of formula (I): wherein m is 1, 2 or 3; n is an integer of any one of 1 to 5; X represents O, S, S(O) or S(O)2; R1 represents a hydrogen atom or a methyl group; R2 and R3 represents a hydrogen atom, an C1-6 alkyl group and the like; when X represents S, S(O) or S(O)2, R4 represents an C1-6 alkyl group, a C1-6 haloalkyl group, an C6-10 aryl group or a five- to six-membered heteroaryl group, and X represents O, S, S(O) or S(O)2, R4 represents an C6-10 aryl group or a five- to six-membered heteroaryl group; G represents a hydrogen atom and the like; Z represents a halogen atom, a cyano group, a nitro group, a phenyl group, an C1-6 alkyl group and the like; is useful as an active ingredient for herbicides.

Abstract translation: 本发明提供了具有优异的防治杂草功效的化合物。 式（I）的二氢吡喃酮化合物：其中m为1,2或3; n为1〜5的任意一个的整数; X表示O，S，S（O）或S（O）2; R1表示氢原子或甲基; R2和R3表示氢原子，C1-6烷基等; 当X表示S，S（O）或S（O）2时，R 4表示C 1-6烷基，C 1-6卤代烷基，C 6-10芳基或五至六元杂芳基， X表示O，S，S（O）或S（O）2，R4表示C6-10芳基或五至六元杂芳基; G表示氢原子等; Z表示卤素原子，氰基，硝基，苯基，C 1-6烷基等; 作为除草剂的活性成分是有用的。

公开(公告)号：US07824659B2

公开(公告)日：2010-11-02

申请号：US11492729

申请日：2006-07-25

Applicant: David S. Casebier ,  Richard R. Cesati, III ,  Edward H. Cheesman

Inventor： David S. Casebier ,  Richard R. Cesati, III ,  Edward H. Cheesman

IPC: A61K51/00 ,  A61M36/14

CPC classification number: C07D237/14 ,  A61K51/0421 ,  A61K51/0459 ,  C07B59/002 ,  C07D237/02 ,  C07D237/16 ,  C07D239/88 ,  C07D311/42

Abstract: The present disclosure relates to a solid-phase process for the production of radiolabeled tracers, in particular for the production of 18F-labeled compounds which may be used as Positron Emission Tomography (PET) radiolabeled tracers. The disclosure also relates to radiopharmaceutical kits comprising precursors to the radiolabeled tracers, which can be converted to the radiolabeled tracers using the processes described herein.

Abstract translation: 本公开内容涉及用于生产放射性标记的示踪剂的固相方法，特别是用于制备可用作正电子发射断层扫描（PET）放射性标记的示踪剂的18F标记的化合物。 本公开还涉及放射性药物试剂盒，其包含放射性标记的示踪剂的前体，其可以使用本文所述的方法转化为放射性标记的示踪剂。

公开(公告)号：US20170158661A1

公开(公告)日：2017-06-08

申请号：US15322582

申请日：2015-07-01

Applicant: Haruo HIGO

Inventor： Haruo HIGO ,  Toshiya MASUDA

IPC: C07D311/42 ,  A23L2/52 ,  A23L33/105 ,  C07C45/41 ,  C07C45/64

CPC classification number: C07D311/42 ,  A23L2/52 ,  A23L33/105 ,  A23V2002/00 ,  C07C45/41 ,  C07C45/46 ,  C07C45/64 ,  C07C45/65 ,  C07C45/81 ,  C07C49/835 ,  C07C49/84 ,  C07D311/32 ,  Y02P20/55 ,  C07C49/813

Abstract: [Problem] To provide a process suitable for mass-producing of iso-liquiritigenin.[Solution] A process for preparing iso-liquiritigenin, which comprises steps of coupling a 4-alkoxycinnamic acid represented by formula (I) with a 1,3-alkoxybenzene represented by formula (II) through the Friedel-Crafts reaction (A) to synthesize a tri-alkoxy-iso-liquiritigenin represented by formula (III), to crystallize out the reaction product, and eliminating the protecting groups therefrom to obtain iso-liquiritigenin, represented by formula (IV). The iso-liquiritigenin (IV), is administered as a precursor for liquiritigenin represented by formula (V) to the body, thereby obtaining in vivo a pharmacological effect of the (−) isomer of liquiritigenin.